---
title: "Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300728153.md"
description: "Dianthus Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4) to six newly hired non-executive employees. The company granted non-qualified stock options for 106,000 shares at $88.32 per share, vesting over four years. These grants serve as material inducements for employment acceptance."
datetime: "2026-10-01T21:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300728153.md)
  - [en](https://longbridge.com/en/news/300728153.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300728153.md)
generator: "portal-rs"
---

# Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 106,000 shares of the Company's common stock with a 10-year term and an exercise price of $88.32 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

**About Dianthus Therapeutics**

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

**Contact**

Jennifer Davis Ruff

Dianthus Therapeutics

jdavisruff@dianthustx.com

### Related Stocks

- [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md)

## Related News & Research

- [Dianthus Therapeutics to present Phase 3 CAPTIVATE interim analysis of claseprubart in CIDP at 2026 AANEM meeting](https://longbridge.com/en/news/300432141.md)
- [Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DNTH Stock News](https://longbridge.com/en/news/284937154.md)
- [SK Hynix Raised USD 26.5B in New York. Does the Memory Cycle Still Apply?](https://longbridge.com/en/news/300876217.md)
- [Summit Therapeutics (SMMT) Teams Up With AstraZeneca And Daiichi Sankyo, Is It 43% Undervalued?](https://longbridge.com/en/news/300872534.md)
- [TECHNICALS-US oil may retest support at $88.78](https://longbridge.com/en/news/300892493.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**